阿片类药物及其受体在泌尿系统恶性肿瘤中的作用:综述
该综述系统检索截至2020年的英文文献,最终纳入33篇文献进行定性分析,探讨阿片类药物及其受体在前列腺癌、膀胱癌和肾癌中的作用。回顾性研究提示围手术期阿片类药物用量增加与前列腺癌或膀胱癌术后更差的无病生存和無复发生存相关,但数据存在争议;体外研究显示阿片受体激动或拮抗对肿瘤增殖、迁移和侵袭有影响。
要点
- 围手术期阿片用量增加可能与前列腺癌或膀胱癌术后更差生存相关,但证据有争议。
- μ阿片受体在前列腺癌组织中染色更强,高表达者肿瘤学结局更差。
- μ、κ和δ阿片受体激动可诱导肾细胞癌肿瘤发生,可能通过上调survivin。
核心结论
- 阿片类药物及其受体在泌尿系统恶性肿瘤中的作用证据具有启发性,应推动进一步研究。
研究设计与样本
- 系统综述,检索截至2020年发表的英文文献,共识别837条独特记录,49篇全文审查,33篇纳入定性分析,另通过引文审查识别8条记录及1项近期全国会议报告研究。
主要发现
- 回顾性研究提示前列腺癌或膀胱癌手术患者围手术期阿片类药物用量增加与更差的无病生存和無复发生存相关,但数据存在争议。
- 体外研究中κ阿片受体在前列腺癌细胞生长中兼具促进增殖和抑制增殖的作用,并可能与雄激素通路相互作用。
- 阿片生长因子受体在前列腺癌细胞中高表达且受雄激素抑制;前列腺癌组织μ阿片受体染色更强,高表达者肿瘤学结局更差。
- 体外阿片受体激动可诱导尿路上皮癌细胞增殖、迁移和侵袭,可能受缓激肽b2受体相互作用影响。
- μ、κ和δ阿片受体激动可诱导肾细胞癌肿瘤发生,可能通过上调survivin;而阿片生长因子受体激动在肾细胞癌中作用相反。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We reviewed the literature surrounding the role of opioids and their receptors in urological malignancy. Recent studies have suggested clinically significant effects of agonism or antagonism of opioid receptors on cancer related outcomes and tumorigenesis. The focus of these efforts has centered on nonurological malignancies. However, a compelling body of evidence is growing in the fields of prostate, bladder and kidney cancer. MATERIALS AND METHODS: A systematic review of English language articles published through 2020 was conducted with key phrases related to kidney, bladder or prostate cancer, and opioids or narcotics. A total of 837 unique records were identified, of which 49 were selected for full text review and 33 were included in the qualitative analysis. Eight records were identified via citation review and 1 study was recently presented at a national meeting. RESULTS: Retrospective reviews suggest poorer disease specific and recurrence-free survival with increased perioperative opioid administration in patients undergoing prostate or bladder cancer surgery. However, the data are controversial. Kappa opioid receptors are implicated in both proliferation and inhibition of prostate cancer cell growth across in vitro studies, with a proposed interaction with the androgen cascade. Similarly opioid growth factor receptor is highly expressed in prostate cancer cells and repressed by androgens. Prostate cancer tissue stains more intensely for the mu opioid receptor, and patients with higher expression have poorer oncologic outcomes. Opioid agonism in vitro induces urothelial cell carcinoma proliferation, migration and invasion, with possible additional influence from interactions with the bradykinin b2 receptor. Agonism of the mu, kappa and delta opioid receptors induces renal cell carcinoma tumorigenesis, possibly via upregulation of survivin. Meanwhile, opioid growth factor receptor agonism has the opposite effect in renal cell carcinoma. CONCLUSIONS: Evidence surrounding the role of opioids and their receptors in urological malignancy is provocative and should serve as an impetus for further investigation.
引用
- Lec PM, Lenis AT, Golla V, et al. The Role of Opioids and Their Receptors in Urological Malignancy: A Review. J Urol. 2020. PMID: 32516030. doi:10.1097/JU.0000000000001156
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。